Ascelia Pharma AB (publ)

Stockholm Stock Exchange ACE.ST

Ascelia Pharma AB (publ) Receivables for the year ending December 31, 2023

Ascelia Pharma AB (publ) Receivables is NA for the year ending December 31, 2023. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Ascelia Pharma AB (publ) Receivables for the year ending December 31, 2019 was USD 0.00.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Stockholm Stock Exchange: ACE.ST

Ascelia Pharma AB (publ)

CEO	Mr. Magnus O. Corfitzen
IPO Date	March 13, 2019
Location	Sweden
Headquarters	Hyllie Boulevard 34
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.

Key trends

Past 5 years